InvestorsHub Logo
Followers 66
Posts 7341
Boards Moderated 0
Alias Born 04/08/2012

Re: CMDawg post# 346281

Thursday, 11/12/2020 1:02:15 PM

Thursday, November 12, 2020 1:02:15 PM

Post# of 403466
Volume isn't important at this point. This has quickly become a long term value play, holding for an inevitable merger or buyout in the next 2-3 years. 40-50 million annual revenues currently, already profitable, on the road to $90-100/annual revs in 2-3 years when XR hits its peak. Now calculate whatever is being worked on in R&D. 4.5x sales rate for pharma purchases= $100 million annual revs x4.5 = $450 million price = .40-.50/share minimum plus the other CNS product being developed that Elite now owns 100% of.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News